ChartRow logo
Data provided bySource: Twelve Data
Share this page

MRNA — Moderna Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in MRNA be worth today? →
MRNA returns: By year · By month · By week · Trailing

Price data

Price
$231.35
YTD price return
+684.50%
YTD total return
+684.50%
Market cap
93.6B
Enterprise value
96.6B
Shares outstanding
404.6M
52W low
$22.28
52W high
$280.80
From 52W high
-17.61%
From 52W low
+938.38%
52W range
81%$22.28–$281
Beta
0.88

Volume

Rel volume
0.42×
30D volume
16.7M
30D $ vol
3.7B

Insider trading

Insider net 1W
none
Insider net 1M
−$8.6M
Insider net 3M
−$33.9M
Insider net 1Y
−$80.9M

Form 4 transactions by trade date, as filed; latest on file 2026-10-15.

Fundamentals

Sales (ttm)
2.5B
Sales/share
$6.24
EPS (ttm)
-$6.91
FCF (ttm)
-2B
FCF/share
-$4.87
Book value/share
$16.90
Net margin
-110.46%
ROE
-40.79%
ROA
-20.71%
Debt / equity
0.52×
Current ratio
3.62

Growth (CAGR, ttm) · 10Y

Sales
+13.14%-34.82%-26.58%+38.13%
Shares
+3.57%+2.00%-0.04%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+9.24%-36.10%-26.55%n/a
Book value/share
-29.26%-21.76%-7.51%n/a
Price
+767.44%+48.85%+0.01%n/a
Total return
+767.44%+48.85%+0.01%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-33.5×
Fwd P/E
-60.8×
P/S (ttm)
37.1×
P/B (mrq)
13.7×
EV/Sales (ttm)
38.3×
FCF yield (ttm)
-2.10%
Buyback yield (realized, 1y)
-3.57%
Shareholder yield (realized, 1y)
-3.57%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
71st
P/B
87th

Bar = where today’s multiple sits in MRNA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-12#

Data provided bySource: Twelve Data
1D
-6.97%
5D
-4.19%
1M
+8.24%
3M
+263.36%
YTD
+684.50%
1Y
+766.15%
5Y
+0.07%
1D
-6.97%
5D
-4.19%
1M
+8.24%
3M
+263.36%
YTD
+684.50%
1Y
+766.15%
5Y
+0.07%

Fundamentals#

Revenue

5Y CAGR +19.3%5Y CAGR +19.3%YoY +29.2%
$2.5B TTM$1.3B Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$2.9B TTM$130M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$6.91 TTM$0.38 Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$2B TTM−$1.6B Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$1.8B, capex −$185M

Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$1.6B, capex −$47M

Shares (diluted)

5Y +2.1%5Y +2.1%YoY +10.3%
403.8M TTM430M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m
−$2.8B TTM$162M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full MRNA financials →

Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.

Cambridge, MA·4,700 employees·Biotechnology·modernatx.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding MRNA#

31 of the 193 ETFs ChartRow carries live hold MRNA. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF2.0%
XBISPDR S&P Biotech ETF1.4%
VHTVanguard Health Care ETF0.6%
VBRVanguard Small-Cap Value ETF0.5%
XLVHealth Care Select Sector SPDR Fund0.4%
VBVanguard Small-Cap ETF0.3%
IWSiShares Russell Mid-Cap Value ETF0.3%
RSPInvesco S&P 500 Equal Weight ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+20.69%-0.70%
JNJJohnson & Johnson+7.50%+1.11%
ABBVAbbVie Inc.+4.74%-0.18%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.03%+0.54%
MRKMerck & Co. Inc.+1.03%-0.16%
NVSNovartis AG+11.41%-0.04%
TMOThermo Fisher Scientific Inc.+5.62%-2.55%
AMGNAmgen Inc.+11.85%-0.22%